SLC5A5, solute carrier family 5 member 5, 6528

N. diseases: 195; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease CTD_human Reduced NIS gene expression in thyroid cancer is likely due in part, to impaired trans-activation at the proximal promoter and/or the upstream enhancer. 16954431 2006
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE We transfected human anaplastic (FRO) and medullary (TT) thyroid cancer-derived cell lines that were unable to take up iodine with human NIS cDNA. 16537683 2006
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Therapeutic disease CTD_human Therefore, tRA treatment and NIS gene transfection are potential tools for the diagnosis and treatment of thyroid cancer. 17045167 2006
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease CTD_human Therefore, tRA treatment and NIS gene transfection are potential tools for the diagnosis and treatment of thyroid cancer. 17045167 2006
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE Reduced NIS gene expression in thyroid cancer is likely due in part, to impaired trans-activation at the proximal promoter and/or the upstream enhancer. 16954431 2006
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE Expression of the sodium iodide symporter (NIS) in the thyroid gland provides for effective imaging and treatment of thyroid cancer using radiolabeled iodide. 15746050 2005
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE The sodium/iodide symporter (NIS) is a membrane glycoprotein that mediates active 131I uptake during the treatment of cancer of the thyroid gland and extrathyroidal tissues. 16264365 2005
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE NIS is a target for radioiodide imaging and therapeutic ablation of thyroid carcinomas and has the potential for similar use in breast cancer treatment. 15472226 2004
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE Qualitative analysis of baseline and stimulated TG, NIS and PDS mRNA showed high sensitivity but low specificity in the prediction of thyroid cancer recurrence or metastases (accuracy under THST = 51%, 43% and 54%, respectively), whereas TPO and TSHR mRNA assays had higher specificity but low sensitivity, with accuracy under THST of 67% and 61%, respectively, that improved when these tests were combined. 15170676 2004
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE The transcriptional regulation of the human sodium/iodide symporter (NIS) gene in normal and transformed thyroid cells is a crucial issue in attempting to restore iodide uptake and use radioiodine as a therapeutic treatment of thyroid cancer. 14630715 2004
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Cloning of the NIS gene and the development of specific NIS antibodies have allowed the characterization of the pathogenic role of NIS in thyroid cancer, thyroid autoimmune diseases, congenital hypothyroidism and other, non-thyroidal human diseases. 14870777 2004
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE The sodium iodide symporter (NIS) mediates iodide uptake in thyroid cells and enables the effective radioiodide treatment of thyroid cancers. 12699587 2003
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Iodination of proteins in TPO transfected thyroid cancer cells is independent of NIS. 15062578 2003
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE Our results have indicated for the first time that reduced levels of CREB expression are a feature of thyroid carcinomas, and confirm that different factors are likely to modulate NIS expression. 12720543 2003
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Radioiodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by a plasma membrane transporter, sodium iodide symporter (NIS), provides a first step mechanism for thyroid cancer detection by radioiodide injection and effective radioiodide treatment for patients with invasive, recurrent, and/or metastatic thyroid cancers after total thyroidectomy. 12477251 2002
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE The increased NIS expression and reduced PDS expression may make radioiodine therapy more effective in patients with thyroid cancer, especially when the tumors have no or low uptake of radioiodine. 12490845 2002
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE Sodium/iodide symporter (NIS) is a key protein in iodide transport by thyroid cells and this activity is a prerequisite for effective radioiodide treatment of thyroid cancer. 12475396 2002
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Radioactive iodide uptake (RAIU) in thyroid follicular epithelial cells, mediated by the sodium iodide symporter (NIS), is the first rate-limiting step in iodide accumulation which provides a mechanism for effective radioiodide treatment for patients with thyroid cancer. 12170377 2002
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE Deficient CRE-like sequence binding protein(s) that bind to the hNUE in normal thyroid cells may be responsible for reduced NIS gene expression in some thyroid carcinomas. 12351692 2002
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE A mammalian NIS expression vector was constructed and used to generate six stable NIS-expressing cancer cell lines (three derived from thyroid carcinoma, two from colon carcinoma, one from glioblastoma). 12111124 2002
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Several investigators have shown that gene transfer of NIS into a variety of cell types confers increased radioiodine uptake by up to several hundredfold that of controls in nonthyroid cancers as well as in thyroid cancer. 12215558 2002
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE Both up- and down-regulation of NIS gene expression have been reported in thyroid cancer using several different methods. 11301345 2001
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 Biomarker disease BEFREE Strategies to restore iodide uptake in thyroid cancer include the exploration of hNIS gene transfer into hNIS defective thyroid cancer. 11573141 2001
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 GeneticVariation disease BEFREE Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas. 11272095 2001
CUI: C0549473
Disease: Thyroid carcinoma
Thyroid carcinoma
0.400 AlteredExpression disease BEFREE In contrast, 2 neoplastic thyroid tissues carrying undetectable PDS mRNA maintained NIS transcript, and 3 thyroid carcinomas negative for NIS mRNA retained the expression of PDS gene. 11454507 2001